ArticleFrontiers in cellular and infection microbiology2025
Distinct gut microbiota and metabolomic profiles in HBV-related liver cirrhosis: insights into disease progression.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Natural Alkaloids Against Liver Injury: Mechanistic Insights and Multi-Target Therapeutic Potential.Biomolecules · 2026Review
- Machine learning-driven clinical decision support for liver cirrhosis: a gut microbiome-based web prediction model with explainable AI integration.BMC gastroenterology · 2026Article
- Interplay between viral infections and gut microbiota dysbiosis: Mechanisms and therapeutic potential.World journal of gastroenterology · 2026Review
- Therapeutic impact of Mongolian Andai therapy on gut microbiota and metabolomic profiles in depression.Frontiers in neuroscience · 2026Article
- Gut microbiota and metabolite profiles in HBV cirrhosis with persistent liver enzyme abnormalities.Frontiers in microbiology · 2025Article
- Gut-liver-muscle axis: linking gut microbiota dysbiosis to malnutrition and sarcopenia in liver disease.Frontiers in medicine · 2025Review
- Advance in molecular mechanisms underlying diabetes related to viral hepatitis infection.Frontiers in cellular and infection microbiology · 2025Review
- A metagenome-wide association study of gut microbiota in hepatitis B virus-related cirrhosis in northwest China.Frontiers in genetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B virus (HBV)-related liver cirrhosis (HBV-LC) is a significant global health issue, affecting gut microbiota (GM) composition and metabolic processes. This study aimed to explore the associations between intestinal microbiota, metabolic profiles, and disease progression in patients with HBV-LC. Methods: Fecal samples were collected prospectively from 40 healthy controls (HC) and 83 HBV-LC patients between December 2022 and August 2023. Gut microbiota alterations at various stages of liver function were analyzed using 16S rRNA gene sequencing. Untargeted metabolomics was employed to identify potential biomarkers and metabolic pathways associated with early cirrhosis. Additionally, correlations between bacterial genera, inflammatory markers, and metabolites were investigated. Results: HBV-LC patients demonstrated a significant reduction in bacterial diversity and relative abundance compared to the HC group. Genera such as Conclusions: HBV-LC patients displayed significant alterations in gut microbiota and fecal metabolites, which correlated closely with disease severity and inflammatory status. These findings provide new insights into cirrhosis pathogenesis and suggest potential biomarkers for early diagnosis and disease monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.